v3.25.4
Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Schedule of Property, Plant and Equipment The useful lives in years are as follows:
Computer software and hardware
3 - 5
Demonstration and consignment inventory5
Furniture and fixtures
7
Leasehold improvements
7
Machinery and equipment
7
Property and equipment, net consisted of the following as of December 31:
20252024
Computer equipment and software$38,403 $41,355 
Demonstration and consignment inventory10,666 9,695 
Leasehold improvements4,343 4,095 
Furniture and fixtures4,769 4,586 
Finance leases15,720 15,737 
Machinery and equipment1,561 1,461 
Assets not yet placed in service701 269 
76,163 77,198 
Less: Accumulated depreciation(54,264)(50,186)
$21,899 $27,012 
Schedule of Finite-Lived Intangible Assets
Finite‑lived intangible assets were initially recorded at fair value upon acquisition and are amortized using the straight‑line method over their estimated weighted‑average useful lives. The useful lives (in years) are as follows:
Weighted Average Useful Life
Intellectual property19.4
Distribution rights9.3
Developed technology9.7
Intangible assets, net consisted of the following as of December 31:
20252024
Intellectual property(a)(b)
$631,507 $626,007 
Distribution rights61,325 61,325 
Customer relationships(c)
— 57,700 
IPR&D(b)
— 5,500 
Developed technology and other13,998 13,998 
Total carrying amount706,830 764,530 
Less accumulated amortization:
Intellectual property(a)(b)
(269,535)(237,829)
Distribution rights(58,783)(54,280)
Customer relationships(c)
— (57,700)
Developed technology and other(9,634)(8,486)
Total accumulated amortization(337,952)(358,295)
Intangible assets, net before currency translation368,878 406,235 
Currency translation(459)(1,506)
$368,419 $404,729 
(a)The Company recorded an impairment loss of $33,901 for the year ended December 31, 2024 within the U.S. reporting segment relating to the net intellectual property solely attributable to the Advanced Rehabilitation Business. The loss was recorded in impairment of assets within the consolidated statements of operations and comprehensive income (loss). Refer to Refer to Note 4. Divestitures for further details regarding businesses held for sale.
(b)The intangible asset previously classified as IPR&D became active during the year ended December 31, 2025, following the receipt of FDA clearance for the TalisMann product. As a result, this intangible asset is now subject to amortization over its estimated useful life, which reflects the period of expected economic benefit.
(c)Customer relationship intangible assets reached the end of their amortizable lives in 2024. The assets were written off in 2025.
Schedule of Fair Value, Concentration of Risk
Certain suppliers provide the Company with product that results in a significant percentage of total sales for the years ended December 31 as follows:
202520242023
Supplier A36%31%27%
Supplier B20%18%17%
Supplier C7%7%8%
Supplier D6%7%7%
Accounts payable to these significant suppliers at December 31 were as follows:
20252024
Supplier A$7,055 $8,876 
Supplier B$175 $948 
Supplier C$— $1,077 
Supplier D$1,235 $2,911 
Certain products provide the Company with a significant percentage of total sales for the years ended December 31 as follows:
202520242023
Product A36%31%27%
Product B15%13%14%
Product C20%18%17%
Product D7%7%8%
Product E6%7%7%